INTRODUCTION: Changes in platelet count and function contribute to thrombo-hemorrhagic episodes in chronic myeloproliferative syndromes (MPS). We used flow cytometry to study platelet-leukocyte conjugates and markers of platelet activation in patients with MPS. METHODS: Whole blood from patients with chronic myelogenous leukemia (CML), polycythemia vera (PV), chronic myelofibrosis (MF), and essential thrombocythemia (ET) and from healthy volunteers was prepared for flow cytometry. Platelet microparticles and platelet microaggregates were identified with anti-CD42b and forward scatter, activated platelets with anti-CD62p. Anti-CD42b, anti-CD14, and anti-CD45 were used to study platelet-leukocyte conjugates. RESULTS: The percentage of CD62p-positive platelets was elevated in all myeloproliferate syndrome subtypes. The median percentage of platelet microparticles was 5.2% in controls and significantly higher in PV (12.0%), MF (11.0%), and ET (11.0%, all p<0.05). There was an increased percentage of platelet-neutrophil conjugates in patients with PV (8.3%) and ET (10.4%) compared to normal controls (6.8%, all p<0.05). Platelet-monocyte conjugates were 8.0% in controls and elevated in PV (15.4%) and ET (15.0%, all p<0.05). Patients with a history of venous or arterial thrombotic events had slightly less platelet-leukocyte conjugates and slightly more microparticles than patients without thrombosis; however, this difference was not statistically significant. CONCLUSIONS: These findings suggest that platelet-leukocyte conjugate formation occurs in myeloproliferative syndromes and indicates platelet activation. Also, platelet microparticles are elevated and might provide a catalytic surface for thrombin generation. This could explain the clinical observation that patients with myeloproliferative syndromes have an increased risk to experience arterial or venous thrombotic events.
INTRODUCTION: Changes in platelet count and function contribute to thrombo-hemorrhagic episodes in chronic myeloproliferative syndromes (MPS). We used flow cytometry to study platelet-leukocyte conjugates and markers of platelet activation in patients with MPS. METHODS: Whole blood from patients with chronic myelogenous leukemia (CML), polycythemia vera (PV), chronic myelofibrosis (MF), and essential thrombocythemia (ET) and from healthy volunteers was prepared for flow cytometry. Platelet microparticles and platelet microaggregates were identified with anti-CD42b and forward scatter, activated platelets with anti-CD62p. Anti-CD42b, anti-CD14, and anti-CD45 were used to study platelet-leukocyte conjugates. RESULTS: The percentage of CD62p-positive platelets was elevated in all myeloproliferate syndrome subtypes. The median percentage of platelet microparticles was 5.2% in controls and significantly higher in PV (12.0%), MF (11.0%), and ET (11.0%, all p<0.05). There was an increased percentage of platelet-neutrophil conjugates in patients with PV (8.3%) and ET (10.4%) compared to normal controls (6.8%, all p<0.05). Platelet-monocyte conjugates were 8.0% in controls and elevated in PV (15.4%) and ET (15.0%, all p<0.05). Patients with a history of venous or arterial thrombotic events had slightly less platelet-leukocyte conjugates and slightly more microparticles than patients without thrombosis; however, this difference was not statistically significant. CONCLUSIONS: These findings suggest that platelet-leukocyte conjugate formation occurs in myeloproliferative syndromes and indicates platelet activation. Also, platelet microparticles are elevated and might provide a catalytic surface for thrombin generation. This could explain the clinical observation that patients with myeloproliferative syndromes have an increased risk to experience arterial or venous thrombotic events.
Authors: Eva Zetterberg; Maria Verrucci; Fabrizio Martelli; Maria Zingariello; Laura Sancillo; Emanuela D'Amore; Rosa Alba Rana; Anna Rita Migliaccio Journal: Platelets Date: 2013-10-31 Impact factor: 3.862
Authors: Ao-Li Zhang; Xiao-Juan Chen; Yao Zou; Wen-Yu Yang; Ye Guo; Shu-Chun Wang; Li Zhang; Xiao-Ming Liu; Min Ruan; Tian-Feng Liu; Ben-Quan Qi; Xiao-Fan Zhu Journal: Zhongguo Dang Dai Er Ke Za Zhi Date: 2019-08
Authors: S Koschmieder; T I Mughal; H C Hasselbalch; G Barosi; P Valent; J-J Kiladjian; G Jeryczynski; H Gisslinger; J S Jutzi; H L Pahl; R Hehlmann; A Maria Vannucchi; F Cervantes; R T Silver; T Barbui Journal: Leukemia Date: 2016-02-08 Impact factor: 11.528
Authors: Marijke C Trappenburg; Muriel van Schilfgaarde; Marina Marchetti; Henri M Spronk; Hugo ten Cate; Anja Leyte; Wim E Terpstra; Anna Falanga Journal: Haematologica Date: 2009-06-08 Impact factor: 9.941
Authors: Marina Karakantza; Nikolaos C Giannakoulas; Panagiotis Zikos; George Sakellaropoulos; Alexandra Kouraklis; Anthi Aktypi; Ioannis C Metallinos; Eleni Theodori; Nicholas C Zoumbos; Alice Maniatis Journal: Int J Hematol Date: 2004-04 Impact factor: 2.490
Authors: Andrew J Murphy; Nora Bijl; Laurent Yvan-Charvet; Carrie B Welch; Neha Bhagwat; Adili Reheman; Yiming Wang; James A Shaw; Ross L Levine; Heyu Ni; Alan R Tall; Nan Wang Journal: Nat Med Date: 2013-04-14 Impact factor: 53.440